Jefferies Starts Lycia Therapeutics at Buy
Bullish analyst initiation; treat the large implied upside cautiously given this is a single target.
Public signal · 1-minute delayed
Source-backed market context you can read and share without an account.
Bullish analyst initiation; treat the large implied upside cautiously given this is a single target.
What happened, with direct paths to the underlying reporting
Jefferies initiated coverage of LYCA with a Buy rating and a $50 target, versus a posted price of $28.61. The target implies substantial upside, but it is a single analyst opinion.
Target: $50
Posted price: $28.61
Analyst firm: Jefferies
Analyst: Faisal Khurshid
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.